Are you out-licensing? Take the Inova Biopharma Survey

22 Jun
Sarah Issa Interview with Sarah Issa, PhD
VP of Marketing, Inova

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

 Gregory Mannix

Gregory Mannix (GM): What is the genesis behind the Biotech Perspective survey?

Sarah Issa (SI): This survey is one of our many efforts to make biopharma partnering more transparent and accessible. There is a clear gap between expectations and reality when it comes to ideal partnerships across all partnering phases: Find, Deal, Alliance. This project was a way to explore our initial assumptions from the biotech perspective as well as learn trends and insights around the current partnering landscape.

GM: How many years has the survey been running?

SI: After the successful launch of the pilot survey in 2022 and resulting report, this year will be the second time we run it.

GM: What kind of results has Inova been seeing?

SI: We had more than 100 biotechs reveal their preferred deal structures, their most common pain points, and rank the world’s largest pharma companies for the quality of their partnering experience. The report has been downloaded more than 800 times so far and the feedback from the readers has been very positive.

Main overall insights:

  • Overall satisfaction with partnerships and partnering has increased over the last 5 years.
  • 78% of biopharma companies rely primarily on conferences to connect with partners.
  • Matching is increasingly difficult: Biotech struggles to find partners, top pharma accepts just 20% of conference meeting requests.

Most selected pain points:

  • In the Find phase: Contacting the appropriate person (61%)
  • In the deal phase: Misaligned expectations (42%)
  • In the alliance management phase: Long or unclear timelines (42%)

GM: Could you share a link of 2022 results with our readers?

SI: The report is available for free on the website à https://go.inova.io/partnering-2030-the-biotech-perspective-2022

GM: What do you hope to gather from this 2023 survey?

SI: In 2023, we want to delve deeper into the main trends we saw in 2022 around the earlier stages of partnering, notably how and where to find a partner, with a focus on partnering congresses.

GM: Is the target audience the same or broader?

SI: The survey is still destined for companies with assets to partner in the biopharma sector and we are accepting participants from across the board (platform/tech, small molecule, medical device, digital health…)

GM: How do you plan to use and publish this 2023 data?

SI: The participant information remains anonymous, we plan on analyzing the results and publishing the report in Q4, distributing it across different channels for the industry. We’ll also be doing a webinar to discuss the results and trends and will invite the highest rating pharma company to share their best practices.

GM: What is Inova’s long-term goal?

SI: At Inova, our mission is to help bring science to life by connecting the right partners and accelerating the partnering process. With our industry-leading CRM, and now, a rapidly growing number of biotechs on our network, we are committed to becoming the leading biopharma match-making platform. By bringing sourcing and execution together, our goal is to offer a holistic solution to partnering, rendering it more effective, faster, cheaper, and accessible to everyone.

Leave a comment